NLRC3

NLR family CARD domain-containing protein 3

1065 amino acids

Negative regulator of the innate immune response (PubMed:15705585, PubMed:22863753, PubMed:25277106). Attenuates signaling pathways activated by Toll-like receptors (TLRs) and the DNA sensor STING/TMEM173 in response to pathogen-associated molecular patterns, such as intracellular poly(dA:dT), but not poly(I:C), or in response to DNA virus infection, including that of Herpes simplex virus 1 (HSV1) (By similarity) (PubMed:22863753). May affect TLR4 signaling by acting at the level of TRAF6 ubiquitination, decreasing the activating 'Lys-63'-linked ubiquitination and leaving unchanged the degradative 'Lys-48'-linked ubiquitination (PubMed:22863753). Inhibits the PI3K-AKT-mTOR pathway possibly by directly interacting with the posphatidylinositol 3-kinase regulatory subunit p85 (PIK3R1/PIK3R2) and disrupting the association between PIK3R1/PIK3R2 and the catalytic subunit p110 (PIK3CA/PIK3CB/PIK3CD) and reducing PIK3R1/PIK3R2 activation. Via its regulation of the PI3K-AKT-mTOR pathway, controls cell proliferation, predominantly in intestinal epithelial cells (By similarity). May also affect NOD1- or NOD2-mediated NF-kappa-B activation (PubMed:25277106). Might also affect the inflammatory response by preventing NLRP3 inflammasome formation, CASP1 cleavage and IL1B maturation (PubMed:25277106).

Belongs to the NLRP family.

114.658 kDa

MRKQEVRTGREAGQGHGTGSPAEQVKALMDLLAGKGSQGSQAPQALDRTPDAPLGPCSNDSRIQRHRKALLSKVGGGPELGGPWHRLASLLLVEGLTDLQLREHDFTQVEATRGGGHPARTVALDRLFLPLSRVSVPPRVSITIGVAGMGKTTLVRHFVRLWAHGQVGKDFSLVLPLTFRDLNTHEKLCADRLICSVFPHVGEPSLAVAVPARALLILDGLDECRTPLDFSNTVACTDPKKEIPVDHLITNIIRGNLFPEVSIWITSRPSASGQIPGGLVDRMTEIRGFNEEEIKVCLEQMFPEDQALLGWMLSQVQADRALYLMCTVPAFCRLTGMALGHLWRSRTGPQDAELWPPRTLCELYSWYFRMALSGEGQEKGKASPRIEQVAHGGRKMVGTLGRLAFHGLLKKKYVFYEQDMKAFGVDLALLQGAPCSCFLQREETLASSVAYCFTHLSLQEFVAAAYYYGASRRAIFDLFTESGVSWPRLGFLTHFRSAAQRAMQAEDGRLDVFLRFLSGLLSPRVNALLAGSLLAQGEHQAYRTQVAELLQGCLRPDAAVCARAINVLHCLHELQHTELARSVEEAMESGALARLTGPAHRAALAYLLQVSDACAQEANLSLSLSQGVLQSLLPQLLYCRKLRLDTNQFQDPVMELLGSVLSGKDCRIQKISLAENQISNKGAKALARSLLVNRSLTSLDLRGNSIGPQGAKALADALKINRTLTSLSLQGNTVRDDGARSMAEALASNRTLSMLHLQKNSIGPMGAQRMADALKQNRSLKELMFSSNSIGDGGAKALAEALKVNQGLESLDLQSNSISDAGVAALMGALCTNQTLLSLSLRENSISPEGAQAIAHALCANSTLKNLDLTANLLHDQGARAIAVAVRENRTLTSLHLQWNFIQAGAAQALGQALQLNRSLTSLDLQENAIGDDGACAVARALKVNTALTALYLQVASIGASGAQVLGEALAVNRTLEILDLRGNAIGVAGAKALANALKVNSSLRRLNLQENSLGMDGAICIATALSGNHRLQHINLQGNHIGDSGARMISEAIKTNAPTCTVEM

Nlrc3

Protein NLRC3

1064 amino acids

Negative regulator of the innate immune response. Attenuates signaling pathways activated by Toll-like receptors (TLRs) and the DNA sensor STING/TMEM173 in response to pathogen-associated molecular patterns, such as intracellular poly(dA:dT), but not poly(I:C), or in response to DNA virus infection, including that of Herpes simplex virus 1 (HSV1) (PubMed:22863753, PubMed:24560620). May affect TLR4 signaling by acting at the level of TRAF6 ubiquitination, decreasing the activating 'Lys-63'-linked ubiquitination and leaving unchanged the degradative 'Lys-48'-linked ubiquitination (PubMed:22863753). Inhibits the PI3K-AKT-mTOR pathway possibly by directly interacting with the posphatidylinositol 3-kinase regulatory subunit p85 (PIK3R1/PIK3R2) and disrupting the association between PIK3R1/PIK3R2 and the catalytic subunit p110 (PIK3CA/PIK3CB/PIK3CD) and reducing PIK3R1/PIK3R2 activation. Via its regulation of the PI3K-AKT-mTOR pathway, controls cell proliferation, predominantly in intestinal epithelial cells (PubMed:27951586). May also affect NOD1- or NOD2-mediated NF-kappa-B activation (By similarity). Might also affect the inflammatory response by preventing NLRP3 inflammasome formation, CASP1 cleavage and IL1B maturation (By similarity).

Belongs to the NLRP family.

115.993 kDa

MRRRYSHDPPGSFRETKVFGFRGEYGCKALVDLLAGKGSQLLQVRDKMPDSPLGSQSNESRIPKHSEALLSRVGNDPELGSPSHRLASLMLVEGLTDLQLKEHDFTQVEATRGVWHPARVITLDRLFLPLSRVSIPPRVSLTIGVAGVGKTTLVRHFVHCWARGQVGKGFSRVLPLTFRDLNTYEKLSADRLIQSIFSSIGEASLVATAPDRVLLVLDGLDECKTPLEFSNTMACSDPKKEIQVDHLITNIIRGNLFPEISVWITSRPSAAGQIPGGLVDRMTEIRGLTEEEIKVCLEQMFPEEQNLLGQVLSQVQANRALYLMCTVPAFCRLTGLALGHLYRTRLAVQDIELPLPQTLCELYSWYFRMALGGEGQDKEKVSPRIKQVTQGARKMVGTLGRLAFHGLVKKKYVFYEQDMKAFGVDLALLQNTLCSCLLQREETLASSVAYCFIHLSLQEFVAATYYYSASKRAIFDLFTESGMSWPRLGFLAHFRCAAQRATQAKDGRLDVFLRFLSGLLSPRVNTLLAGSLLSQGEHQSYRDQVAEVLQGFLHPDAAVCARAINVLYCLSELRHTELACSVEEAMRSGTLAGMTSPSHRTALAYLLQMSDICSPEADFSLCLSQHVLQSLLPQLLYCQSLRLDNNQFQDPVMELLGSVLSGKDCRIRKISLAENQIGNKGAKALARSLLVNRSLITLDLRSNSIGPPGAKALADALKINRTLTSLSLQSNVIKDDGVMCVAEALVSNQTISMLQLQKNLIGLIGAQQMADALKQNRSLKALMFSSNTIGDRGAIALAEALKVNQILENLDLQSNSISDMGVTVLMRALCSNQTLSSLNLRENSISPEGAQALTQALCRNNTLKHLDLTANLLHDRGAQAIAVAVGENHSLTHLHLQWNFIQAGAARALGQALQLNRTLTTLDLQENAIGDEGASSVAGALKVNTTLIALYLQVASIGSQGAQALGEALTVNRTLEILDLRGNDVGAAGAKALANALKLNSSLRRLNLQENSLGMDGAIFVASALSENHGLHHINLQGNPIGESAARMISEAIKTNAPTCTVEI